Researcher
Franki Speleman
- Disciplines:Cell signalling, Cellular interactions and extracellular matrix, Cytoskeleton, Epigenetics, Cell death, Cell division, Cell growth and development, Cell movement, Transcription and translation, Medical epigenomics, Medical metagenomics, Medical genomics, Genetics, Molecular and cell biology not elsewhere classified, Intracellular compartments and transport, Membrane structure and transport, Posttranslational modifications, Stem cell biology, Structural biology, Immunogenetics, Clinical genetics and molecular diagnostics
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
1 - 10 of 44
- Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate studentsFrom1 May 2024 → TodayFunding: BOF - doctoral mandates
- Spatial-omics deciphering of cellular and molecular responses to enhanced MYCN/ATR-CHK1 synthetic lethality in high-risk neuroblastomaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Incucyte S3: Comprehensive cellular phenotyping using high-throughput live cell imagingFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- SpatialConnect: linking tissue biology to the new era of single-cell spatial transcriptomicsFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)From1 Jan 2022 → TodayFunding: BOF - projects
- Scrutinizing selective Aurora Kinase A inhibition as a novel entry point for synthetic lethality in neuroblastomaFrom1 Nov 2021 → TodayFunding: FWO fellowships
- The role of the SOX11 lineage-dependency factor as epigenetic master regulator in neuroblastomaFrom1 Oct 2021 → TodayFunding: BOF - projects
- The role of BRIP1 in MYCN driven neuroblastoma formation: from mechanism to druggingFrom1 Jan 2021 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
- Targeting the degradation of proteins involved in neuroblastoma with bivalent ligands.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
Publications
31 - 40 of 91
- A mechanistic classification of clinical phenotypes in neuroblastoma(2018)Volume: 65
Authors: S Ackermann, M Cartolano, B Hero, A Roderwieser, C Bartenhagen, C Rosswog, F Hertwig, T Simon, A Eggert, Franki Speleman, et al.
Pages: S87 - S88 - Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients(2018)
Authors: Fjoralba Zeka, Anneleen Decock, Alan Van Goethem, Katrien Vanderheyden, Fleur Demuynck, Tim Lammens, Hetty Helsmoortel, Joëlle Vermeulen, Rosa Noguera, Ana P. Berbegall, et al.
- BRCA1 hypomethylation causes chemoresistance in high-risk neuroblastoma(2017)Volume: 64
Authors: A Hakkert, M Ebus, J Koster, Franki Speleman, R Versteeg, H Heyn, J Molenaar
Pages: S121 - S122 - Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait(2016)
Authors: Anneleen Decock, Maté Ongenaert, Bram De Wilde, Bénédicte Brichard, Rosa Noguera, Franki Speleman, Jo Vandesompele
Pages: 761 - 771 - Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers(2015)
Authors: André Oberthuer, Dilafruz Juraeva, Barbara Hero, Ruth Volland, Carolina Sterz, Rene Schmidt, Andreas Faldum, Yvonne Kahlert, Anne Engesser, Shahab Asgharzadeh, et al.
Pages: 1904 - 1915 - Integrated genomic analysis identifies specific alterations and activation of YAP in relapsed neuroblastoma(2015)Volume: 62
Authors: A Eggert, A Schramm, J Koester, Y Assenov, A Kristina, A Engesser, Y Kahlert, J Theissen, B Hero, F Roels, et al.
Pages: S145 - S145 - Mutational dynamics between primary and relapse neuroblastomas(2015)
Authors: Alexander Schramm, Johannes Köster, Yassen Assenov, Krstina Althoff, Martin Peifer, Ellen Mahlow, Andrea Odersky, Daniela Beisser, Corinna Ernst, Anton G Henssen, et al.
Pages: 872 - 877 - The first lncRNA landscape of major genetic T-ALL subsets and guilt-by-association analysis for ETP-ALL specific lncRNAs(2014)Volume: 99
Authors: Annelynn Wallaert, Kaat Durinck, Wouter Van Loocke, Pieter-Jan Volders, Inge Van de Walle, Yves Benoit, Bruce Poppe, Jo Vandesompele, Tom Taghon, Jean Soulier, et al.
Pages: 2 - 3 - Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma(2014)
Authors: Eveline Barbieri, Katleen De Preter, Mario Capasso, Zaowen Chen, Danielle M Hsu, Gian Paolo Tonini, Steve Lefever, John Hicks, Rogier Versteeg, Andrea Pession, et al.
Pages: 765 - 774 - Emergence of new ALK mutations at relapse of neuroblastoma(2014)
Authors: Gudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, Quentin Leroy, Julie Cappo, Thomas Rio Frio, Gaëlle Pierron, Eve Lapouble, Valérie Combaret, Franki Speleman, et al.
Pages: 2727 - 2734
Patents
1 - 1 of 1